CalciMedica Reports Q2 2025 Financial and Clinical Updates
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting...
Category : Clinical Research, Pharma & Healthcare Financing
Acurx Pharma Reports Q2 Results and Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain...
Stoke & Biogen Dose First Patient in EMPEROR Study
Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period Dravet syndrome is a rare...
Tahoe Therapeutics Raises $30M for AI Cell Modeling
One billion cells to power the next generation of AI models in biology Tahoe Therapeutics today announced $30 million in new funding to build the definitive...
SetPoint Raises $140M, Expands Team for RA Therapy
SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, announced that it has raised $140 million in private financing,...
Equillium Raises Up to $50M to Advance EQ504 to Clinic
Financing led by ADAR1 Capital Management and Janus Henderson Investors $30 million up front with the potential to receive an additional $20 million at clinical...
IVD Medical Invests HK$149M in Ethereum via HashKey
HashKey Exchange, Hong Kong’s largest * licensed virtual asset trading platform, has entered into a strategic partnership with IVD Medical Holdings Limited, a publicly listed company on the...
LabConnect, Kits4Life Partner to Cut Clinical Kit Waste
As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership with Kits4Life, an...
Prelude Growth Invests $20M in OneSkin for Longevity Push
OneSkin, the pioneering skin longevity brand, powered by biotech and grounded in science, is proud to announce a $20 million Series A investment from growth equity firm...
Strand Therapeutics Raises $153M to Advance mRNA Pipeline
Funding will advance Strand’s pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead program, STX-001,...
Cybin Gains EU Approval for EMBRACE Phase 3 Depression Study
EMBRACE, the second study within the Phase 3 PARADIGM program, will enroll 330 participants at approximately 60 clinical sites across the United States, Europe, the United...
KORU Medical Reports Q2 2025 Revenue Growth, Raises Guidance
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric...
Cresco Labs Commits to Refinancing Senior Secured Credit Facility
Will Reduce Debt and Reinforces Commitment to Prudent Capital Management Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today...
FDA Expands Use of AVTOZMA® for CRS Treatment
Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA® (tocilizumab-anoh) to...
Polpharma Biologics, Fresenius Kabi License Vedolizumab Biosimilar
Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016,...